Huntington's Disease Mechanistic Pathway

Migration, Crosslink

📖

Huntington's Disease Mechanistic Pathway

active

wiki page Created: 2026-04-02T07:20:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-huntington-pathway

📖 Wiki Page

mechanism942 wordssynced 2026-04-02

Huntington's Disease Mechanistic Pathway

Introduction

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expanded CAG trinucleotide repeat in the [HTT](/genes/htt) gene, which encodes the huntingtin protein. The pathogenic expansion results in a mutant huntingtin protein (mHTT) with an expanded polyglutamine (polyQ) tract that gains toxic functions while losing normal protective activities. This page outlines the key molecular and cellular mechanisms driving HD pathogenesis.

Overview

| Property | Value |
|----------|-------|
| Causative Gene | [HTT](/genes/htt) (Huntingtin) |
| Mutation | CAG trinucleotide repeat expansion |
| Normal CAG Repeats | ≤26 |
| Pathogenic CAG Repeats | ≥36 |
| Protein Product | Huntingtin protein (3,144 amino acids) |
| Primary Brain Regions Affected | Striatum (caudate, putamen), cerebral cortex |
| Key Pathological Features | mHTT aggregates, striatal neuron loss, cortical atrophy |

Molecular Mechanisms

Mutant Huntingtin Toxicity

The expanded polyglutamine tract in mutant huntingtin (mHTT) leads to toxic gain-of-function through multiple interconnected mechanisms:

Protein Misfolding and Aggregation

The expanded polyQ tract causes conformational changes and protein misfolding
mHTT forms soluble oligomers and insoluble aggregates in neurons
Aggregates are found in striatum, cortex, and other brain regions[@saudou2016]
Both nuclear and cytoplasmic inclusions contribute to toxicity

...

Huntington's Disease Mechanistic Pathway

Introduction

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expanded CAG trinucleotide repeat in the [HTT](/genes/htt) gene, which encodes the huntingtin protein. The pathogenic expansion results in a mutant huntingtin protein (mHTT) with an expanded polyglutamine (polyQ) tract that gains toxic functions while losing normal protective activities. This page outlines the key molecular and cellular mechanisms driving HD pathogenesis.

Overview

| Property | Value |
|----------|-------|
| Causative Gene | [HTT](/genes/htt) (Huntingtin) |
| Mutation | CAG trinucleotide repeat expansion |
| Normal CAG Repeats | ≤26 |
| Pathogenic CAG Repeats | ≥36 |
| Protein Product | Huntingtin protein (3,144 amino acids) |
| Primary Brain Regions Affected | Striatum (caudate, putamen), cerebral cortex |
| Key Pathological Features | mHTT aggregates, striatal neuron loss, cortical atrophy |

Molecular Mechanisms

Mutant Huntingtin Toxicity

The expanded polyglutamine tract in mutant huntingtin (mHTT) leads to toxic gain-of-function through multiple interconnected mechanisms:

Protein Misfolding and Aggregation

The expanded polyQ tract causes conformational changes and protein misfolding
mHTT forms soluble oligomers and insoluble aggregates in neurons
Aggregates are found in striatum, cortex, and other brain regions[@saudou2016]
Both nuclear and cytoplasmic inclusions contribute to toxicity

Loss of Normal Huntingtin Function

Wild-type huntingtin is essential for neuronal survival
Normal HTT regulates neurotrophic factor production (BDNF)
HTT participates in vesicle trafficking and autophagy
The mutation disrupts these essential protective functions[@lands2012]

Transcriptional Dysregulation

Mutant huntingtin disrupts gene expression through multiple mechanisms:

Transcription Factor Sequestration

mHTT sequesters transcription factors including REST, NCoR, and p53
REST mislocalization leads to dysregulation of neuronal genes
Histone acetylation defects impair chromatin accessibility[@hunt2011]

DNA Damage and Repair

mHTT impairs DNA repair mechanisms
Accumulation of DNA damage in neurons
Transcriptional programs critical for neuronal function are disrupted

Gene Expression Changes

Downregulation of neurotrophic factors (BDNF)
Loss of neuronal identity markers
Upregulation of inflammatory genes

Mitochondrial Dysfunction

Mitochondrial impairment is a central feature of HD pathogenesis:

Energy Metabolism Defects

Reduced complex I, II, and III activity in striatum
Decreased ATP production capacity
Increased sensitivity to metabolic stress[@gu2011]

PGC-1α Dysregulation

Reduced PGC-1α expression and activity
Impaired mitochondrial biogenesis
Defective mitochondrial quality control[@kim2010]

Mitochondrial Dynamics

Altered fission/fusion balance
Increased mitochondrial fragmentation
Impaired mitochondrial transport

Calcium Handling

Dysregulated calcium signaling
Increased sensitivity to excitotoxicity
Impaired mitochondrial calcium uptake

Signaling Pathways

Mermaid diagram (expand to render)

Key Molecular Interactions

mTOR Pathway: Impaired autophagy leads to accumulation of mHTT aggregates

BDNF Signaling: Reduced trophic support contributes to neuronal vulnerability

CREB Signaling: Transcriptional dysfunction affects neuronal survival genes

Calcium Signaling: Excitotoxicity via NMDA receptor overactivation

NF-κB Pathway: Neuroinflammation via microglial activation[@taylor2016]

Cellular Mechanisms

Striatal Medium Spiny Neuron Vulnerability

The striatum, particularly medium spiny neurons (MSNs), shows the earliest and most severe degeneration in HD:

MSNs comprise 90% of striatal neurons
D1- and D2-expressing MSNs both affected
Early loss of indirect pathway neurons contributes to chorea
Loss of direct pathway neurons leads to bradykinesia

Cortical Involvement

Progressive cortical degeneration accompanies striatal loss:

Layer 3 and 5 pyramidal neurons show vulnerability
Corticostriatal connectivity is disrupted
Contributes to cognitive impairment

Neuroinflammation

Microglial activation is prominent throughout HD progression:

Increased TSPO binding on PET imaging
Elevated cytokines in CSF and brain tissue
Contributes to disease progression[@taylor2016]

Genetic Modifiers

Recent genetic studies have identified modifiers of HD onset and progression:

| Gene | Modifier Effect | Reference |
|------|-----------------|-----------|
| MSH3 | Modifies age at onset; DNA mismatch repair | [@sportelli2020] |
| FAN1 | DNA repair nuclease; onset modifier | |
| RHA | Repeat-binding protein | |
| RAN | Translation of Repeat-Containing Proteins | |

Therapeutic Targets

| Target | Approach | Development Status |
|--------|----------|-------------------|
| HTT Gene | ASO gene silencing (Tominersen) | Phase 3 (GENERATION-HD2) |
| HTT Gene | AAV RNAi delivery | Preclinical |
| Mutant Protein | Aggregation inhibitors | Research |
| Transcriptional dysfunction | HDAC inhibitors | Phase 2 |
| Mitochondrial function | PGC-1α activators | Research |
| Neuroinflammation | Microglial modulation | Research |
| BDNF signaling | BDNF mimetics | Research |

Cross-Linked Pages

[HTT Gene](/genes/htt)
[Huntingtin Protein](/proteins/huntingtin-protein)
[Huntington's Disease](/diseases/huntingtons)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration)
[Neuroinflammation](/mechanisms/neuroinflammation-pathway)
[Transcriptional Dysregulation](/mechanisms/transcriptional-dysregulation)
[Striatal Selective Vulnerability](/mechanisms/striatal-selective-vulnerability-huntingtons)

References

Unknown (n.d.)

[Saudou & Humbert, The Biology of Huntingtin (2016)](https://doi.org/10.1016/j.neuron.2016.02.003)

[Tabrizi et al., Biological and clinical manifestations of HD (2019)](https://doi.org/10.1016/S1474-4422(19)30347-6)

[Lands et al., Huntington's disease: underlying molecular mechanisms (2012)](https://doi.org/10.1007/s00401-012-0989-1)

[Hunt & Ryu, Transcriptional dysregulation in Huntington's disease (2011)](https://doi.org/10.1016/j.tins.2011.06.005)

[Gu et al., Mitochondrial dysfunction in Huntington's disease (2011)](https://doi.org/10.1172/JCI43665)

[Kim et al., Impaired mitochondrial function in Huntington's disease (2010)](https://doi.org/10.1038/nrneurol.2010.60)

[Taylor et al., Neuroinflammation in Huntington's disease (2016)](https://doi.org/10.1038/nrneurol.2016.71)

[Creighton et al., Mutant huntingtin aggregation and cellular toxicity (2020)](https://doi.org/10.3233/JHD-200003)

[Kumar et al., Synaptic dysfunction in Huntington's disease (2020)](https://doi.org/10.1016/j.nbd.2020.104904)

[Sportelli et al., Genetic modifiers of Huntington's disease (2020)](https://doi.org/10.3233/JHD-200391)

📖 View canonical wiki page →

Related Entities

mechanisms-huntington-pathway

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-huntington-pathway
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f17ce969bfbb
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-huntington-pathway'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

59

Outgoing

73

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Huntington's Disease Mechanistic Pathway

Huntington's Disease Mechanistic Pathway

Introduction

Overview

Molecular Mechanisms

Mutant Huntingtin Toxicity

Huntington's Disease Mechanistic Pathway

Introduction

Overview

Molecular Mechanisms

Mutant Huntingtin Toxicity

Transcriptional Dysregulation

Mitochondrial Dysfunction

Signaling Pathways

Key Molecular Interactions

Cellular Mechanisms

Striatal Medium Spiny Neuron Vulnerability

Cortical Involvement

Neuroinflammation

Genetic Modifiers

Therapeutic Targets

Cross-Linked Pages

References

💬 Discussion